Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

(2010) Andrew D. Goodman et al.   ANNALS OF NEUROLOGY

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis

(2010) S. Belachew et al.   EUROPEAN JOURNAL OF NEUROLOGY

Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-Release 10-mg tablets in patients with multiple sclerosis: A 2-week, open-label, follow-up study

(2009) Timothy Vollmer et al.   CLINICAL THERAPEUTICS

Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: A phase I–II, open-label trial

(2009) Timothy Vollmer et al.   CLINICAL THERAPEUTICS

Seizures in Patients with Multiple Sclerosis

(2009) Brendan J. Kelley et al.   CNS DRUGS

Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals

(2009) Barrie March et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Single-Dose Pharmacokinetics of Sustained-Release Fampridine (Fampridine-SR) in Healthy Volunteers and Adults With Renal Impairment

(2009) William Smith et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial

(2009) Andrew D Goodman et al.   LANCET

Seizures in multiple sclerosis

(2008) Marcus Koch et al.   EPILEPSIA

4-AMINOPYRIDINE TOXICITY WITH UNINTENTIONAL OVERDOSE IN FOUR PATIENTS WITH MULTIPLE SCLEROSIS

(2008) J. M. Burton et al.   NEUROLOGY

Dose comparison trial of sustained-release fampridine in multiple sclerosis

(2008) A. D. Goodman et al.   NEUROLOGY